Integra LifeSciences Holdings Co. (NASDAQ:IART) Shares Sold by Geode Capital Management LLC

Geode Capital Management LLC lowered its position in Integra LifeSciences Holdings Co. (NASDAQ:IART) by 0.2% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,823,994 shares of the life sciences company’s stock after selling 3,854 shares during the period. Geode Capital Management LLC’s holdings in Integra LifeSciences were worth $33,148,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the company. KBC Group NV raised its holdings in Integra LifeSciences by 65.2% in the 3rd quarter. KBC Group NV now owns 2,839 shares of the life sciences company’s stock worth $52,000 after purchasing an additional 1,120 shares during the period. Canada Pension Plan Investment Board purchased a new stake in shares of Integra LifeSciences in the second quarter valued at approximately $114,000. Northwest Investment Counselors LLC acquired a new position in shares of Integra LifeSciences during the 3rd quarter worth approximately $73,000. Allspring Global Investments Holdings LLC grew its stake in Integra LifeSciences by 58.0% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 4,662 shares of the life sciences company’s stock valued at $136,000 after acquiring an additional 1,711 shares during the period. Finally, Centiva Capital LP purchased a new stake in Integra LifeSciences in the 3rd quarter worth $192,000. 84.78% of the stock is owned by hedge funds and other institutional investors.

Integra LifeSciences Stock Performance

NASDAQ IART opened at $22.13 on Thursday. Integra LifeSciences Holdings Co. has a fifty-two week low of $16.81 and a fifty-two week high of $45.42. The firm has a market capitalization of $1.71 billion, a P/E ratio of -245.86, a price-to-earnings-growth ratio of 0.82 and a beta of 1.15. The stock’s fifty day moving average is $22.69 and its two-hundred day moving average is $23.24. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings data on Monday, November 4th. The life sciences company reported $0.41 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.39 by $0.02. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The firm had revenue of $380.80 million during the quarter, compared to analyst estimates of $375.81 million. During the same quarter in the prior year, the firm posted $0.76 earnings per share. Integra LifeSciences’s quarterly revenue was down .4% on a year-over-year basis. On average, research analysts anticipate that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have issued reports on IART. Bank of America decreased their price objective on shares of Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating on the stock in a report on Monday, October 7th. BTIG Research upgraded Integra LifeSciences from a “sell” rating to a “neutral” rating in a report on Monday, October 7th. Truist Financial reduced their target price on Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating for the company in a report on Monday, October 14th. Citigroup boosted their price target on Integra LifeSciences from $16.00 to $22.00 and gave the stock a “sell” rating in a research report on Tuesday, November 5th. Finally, Morgan Stanley assumed coverage on Integra LifeSciences in a report on Monday, December 2nd. They issued an “underweight” rating and a $20.00 price objective on the stock. Three analysts have rated the stock with a sell rating, five have given a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $23.00.

Insider Activity

In other Integra LifeSciences news, EVP Michael J. Mcbreen sold 1,700 shares of the firm’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $24.16, for a total transaction of $41,072.00. Following the completion of the sale, the executive vice president now owns 56,182 shares of the company’s stock, valued at $1,357,357.12. This trade represents a 2.94 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 3.10% of the company’s stock.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.